Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 7/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL695498 | 0.89 | MAP2K1 (0.41) | MAP2K1 | |
| SCHEMBL693009 | 0.88 | RXFP1 (0.35) | MAP2K1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1516498 | 0.73 | CASP3 (0.36) | MAP2K1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL684564 | 0.72 | MAPK13 (0.39) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL13148448 | 0.70 | MAP2K1 (0.40) | MAP2K1 | |
| SCHEMBL388455 | 0.70 | MAPK13 (0.34) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL697676 | 0.69 | MAP2K1 (0.39) | MAP2K1 | |
| SCHEMBL699800 | 0.68 | MEN1 (0.39) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL3794238 | 0.68 | MAP2K1 (0.64) | MAP2K1 | |
| SCHEMBL486496 | 0.68 | MAP2K1 (0.39) | MAP2K1MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421612-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | Novartis AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010121646-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | NOVARTIS AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010121646-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | NOVARTIS AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NRAS, BRAF, MAP3K1 | MAP2K1 48/4885MAPK13 44/4885MAPK12 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.